2016
DOI: 10.1200/jco.2016.68.1478
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Purpose Treatment with pembrolizumab, an anti-programmed death-1 antibody, at 10 mg/kg administered once every 2 weeks, displayed durable antitumor activity in programmed death-ligand 1 (PD-L1) -positive recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) in the KEYNOTE-012 trial. Results from the expansion cohort, in which patients with HNSCC, irrespective of biomarker status, received a fixed dose of pembrolizumab at a less frequent dosing schedule, are reported. Patients and Meth… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

20
624
1
4

Year Published

2017
2017
2019
2019

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 703 publications
(649 citation statements)
references
References 32 publications
20
624
1
4
Order By: Relevance
“…HPV-positive HNSCC harbor fewer mutations [28] and present a higher response to anti-PD1 when compared to HPV-negative HNSCC [14,15,29]. In the case of viral-induced carcinogenesis, viral antigens likely represent dominant antigens that stimulate T-cells reactivity and contribute to the inflamed tumor phenotype and IFN-γ activation.…”
Section: Discussionmentioning
confidence: 99%
“…HPV-positive HNSCC harbor fewer mutations [28] and present a higher response to anti-PD1 when compared to HPV-negative HNSCC [14,15,29]. In the case of viral-induced carcinogenesis, viral antigens likely represent dominant antigens that stimulate T-cells reactivity and contribute to the inflamed tumor phenotype and IFN-γ activation.…”
Section: Discussionmentioning
confidence: 99%
“…5 Pembrolizumab is also approved for use in advanced NSCLC, HNSCC, Hodgkin lymphoma, urothelial cancer, and microsatellite instabilityhigh cancer. 11,[28][29][30] Atezolizumab, the first commercially available PD-L1 inhibitor, received accelerated approval in May 2016 for locally advanced or metastatic urothelial carcinoma after failure of platinum-containing chemotherapy and is now also approved for NSCLC. 12,13,17 In 2017, 2 further PD-L1 inhibitors received accelerated FDA approval: avelumab for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma 15,31 and durvalumab for locally advanced or metastatic urothelial carcinoma after failure of platinum-containing chemotherapy.…”
Section: Clinical Pharmacology Of Checkpoint Inhibitorsmentioning
confidence: 99%
“…The immunologic profile of the tumor can be taken into consideration when selecting appropriate patients. The level of PD-L1 expression within tumor cells and/or immune cells is associated with higher ORR or longer OS following treatment wi th PD-1/PD-L1 blockers in N SCLC and UC, pembrolizumab in HNSCC, and nivolumab in melanoma [23,24,27,32,41,42,44,49,54,60,62]. However, some patients with low or no levels of PD-L1 expression also respond to ICBs [27], indicating that PD-L1 expression is enriched for responders, but the absence of expression is not an absolute indicator of lack of benefit.…”
Section: Immunotherapeutics and Patient Selectionmentioning
confidence: 99%
“…The development of granulomatous changes in the lymph nodes resembling progression have also been described during immunotherapy treatment [114]. In studies investigating immunotherapies in patients with cancer, the prevalence of pseudoprogression can vary based on tumor type; for example, it has been reported to be 7% to 10% in melanoma [23,113,115], 5% to 7% in NSCLC [25,27], 7% in UC [54], and 0% to 2% in HNSCC [44,116].…”
Section: Pseudoprogression With Icbsmentioning
confidence: 99%